P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153 David Spigel,

Slides:

Advertisements

Similar presentations

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Advertisements

A2-06: Survival differences for non-Bronchioloalveolar Carcinoma (BAC) non-small-cell lung cancer (NSCLC) cases with ipsilateral intrapulmonary metastasis.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

SC17.02 Lung Cancer in China: Challenges and Perspectives

A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients.

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

P3.02c-030 Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC) Edward Garon, Martin Reck, Delvys.

P The Effect of Two Interventions on Attainment of Surgical Quality Measures in Resected Non-Small Cell Lung Cancer (NSCLC) Nicholas Faris, Meredith.

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

P The Impact of IASLC 8th Edition Updates for T-Classification for Lung Cancer in a US Population-Based Surgical Resection Cohort Matthew Smeltzer,

P Risk Stratification Model to Predict Survival Following Surgical Resection for Lung Cancer Using Pathological Variables Timothy Edwards, Charlene.

P2.33: Safety Profile of Nivolumab Administered as 30-Minute (MIN) Infusion: Analysis of Data From Checkmate 153 David Waterhouse, Leora Horn, Craig.

P3.02c-088 Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Jungmin Choi, Ryan Sowell, Anna Truini, Kurt.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC) Taofeek Owonikoko,

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

P Molecular Characterization of Non-Small Cell Lung Cancers (NSCLC) in Young Patients from an Argentine Population V. Denninghoff, G. Recondo,

P SARON: Stereotactic Ablative Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer (NSCLC). A UK Randomized Phase III Trial Yenting Ngai,

P Phase 1/2 Trial of WT1 TCR-Transduced Central Memory and Naïve CD8+T Cells for Patients with Mesothelioma and Non-Small Cell Lung Cancer Sylvia.

PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First-Line ± Standard-of-Care Therapies in Advanced NSCLC

Elizabeth B. Gottlin, PhD, Rex C. Bentley, MD, Michael J

P3.02b-125 Failure to Tyrosine Kinase Inhibitors and Patterns of Progression in Patients with Advanced Non-Small Cell Lung Cancer Feliciano Barron, Laura-Alejandra.

P3.02b-075 Addition of Bevacizumab for Malignant Pleural Effusion as the Manifestation of Acquired EGFR-TKI Resistance in NSCLC Patients Tao Jiang, Shengxiang.

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

P3.02b-062 Safety of Necitumumab and Abemaciclib Combination Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Benjamin Besse, Johan.

P Predictors of Survival after Whole Brain Radiotherapy for Patients with Brain Metastasized Lung Cancer Georgios Tsakonas, Fatou Hellman, Signe.

PS02.17 A Biomarker-Driven Algorithm for Sequencing of Systemic Therapy for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Survey of 25 Investigators

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

ED11.01 Systemic Therapy for Advanced Oncogene-Driven NSCLC

P3.02c-028 Outcomes of Nivolumab in Elderly Patients (pts) with Non-Small Cell Lung Cancer (NSCLC) Stephen Bagley, Shawn Kothari, Charu Aggarwal, Joshua.

P3.02b-061 A Phase II Study of Nab-Paclitaxel (Nab-P) in Patients with Advanced Non- Small Cell Lung Cancer (NSCLC) with EGFR Mutations Christina Baik,

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Heidi B. Rolke, Frode Gallefoss Journal of Thoracic Oncology

P Accuracy of Combined Semantic and Computational CT Features in Predicting Non-Small Cell Lung Cancer Subtype Usman Bashir, Andrea Bille, Levon.

ES Lung Cancer Surgery for High Risk Patients

P Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Nicola.

MTP13-01: Indications and limitations of bronchoscopy

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

MA Comparison of EORTC, PERCIST, PeterMac & Deauville PET Response Criteria after Radical ChemoRT in Non-Small-Cell Lung Cancer G. Turgeon, A.

P3.02a-023 Treatment Patterns and Early Outcomes of ALK+ Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study Edmond Bendaly,

A2-06: Survival differences for non-Bronchioloalveolar Carcinoma (BAC) non-small-cell lung cancer (NSCLC) cases with ipsilateral intrapulmonary metastasis.

M. Kusumoto Journal of Thoracic Oncology

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

MA12.05 Can Tumor Spread through Air Spaces (STAS) in Lung Adenocarcinomas Be Predicted Pre- and Intraoperatively? Koji Kameda, Shaohua Lu, Takashi Eguchi,

European Lung Cancer Conference (ELCC) 2016 Organisation

OA Video-Assisted Thoracoscopic Surgery vs

MINI01. 20: Interim Quality of Life (QoL) Results from ABOUND

P2.03b-002 Efficacy and Safety of WBRT Combined with Endostar in Patients with Advanced Non-Small Cell Lung Cancer Xiaorong Dong, Ruiguang Zhang, Xican.

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

PS01.07 The Clinical Necessity of Extended Thymectomy for Thymic Squamous Cell Carcinomas Revealed by Exome Sequencing J. Jiang, Y. Zhang, C. Jin, J.

IASLC 6th Latin American Conference on Lung Cancer

P Nivolumab for Non-Small Cell Lung Cancer (NSCLC): An Economic Model for Risk Sharing Based on Real-Life Data Elizabeth Dudnik, Daniel Goldstein,

P Post-Recurrence Survival Analysis of Stage I Non-Small Cell Lung Cancer: Prognostic Significance of Local Treatment Kanghoon Lee, Hyeong Ryul.

PUB006 Impact of the New WHO Classification of Thymic Tumors: Cross-Validation of the Prognostic Value in a Single Institution Cohort Mohamed Kamel,

OA Survival Trends Among Non-Small Cell Lung Cancer (NSCLC) Patients Over A Decade: Impact of Initial Therapy at Academic Centers B. Dholaria,

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

M. Pasquinelli, Z. Deliu, D. Rosenberg, C. Weldon, S. Obilade, A

A Review of First-Line Treatment for Small-cell Lung Cancer

Mark A. Socinski, MD Journal of Thoracic Oncology

MA01.03 The Non-Invasive LuCED® Test for Detection of Early Stage Lung Cancer Michael Meyer, Timothy Bell, Daniel Sussman, David Wilbur, Chris Presley,

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153 David Spigel, Lee Schwartzberg, David Waterhouse, Jason Chandler, Maen Hussein, Robert Jotte, Edward Stepanski, Michael Mccleod, Ray Page, Rohini Sen, Jeffrey Mcdonald, Kelly Bennett, Beata Korytowsky, Nivedita Aanur, Craig Reynolds Journal of Thoracic Oncology Volume 12, Issue 1, Pages S1287-S1288 (January 2017) DOI: 10.1016/j.jtho.2016.11.1821 Copyright © 2016 Terms and Conditions

Journal of Thoracic Oncology 2017 12, S1287-S1288DOI: (10.1016/j.jtho.2016.11.1821) Copyright © 2016 Terms and Conditions